{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-290428","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2021-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.770429+00:00","generated_at":"2026-06-28T23:23:39.262364+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"CytomX appoints Alan Ashworth, Ph.D., FRS to Board of Directors as Class III director","bullets":["Appointment effective Sept 29, 2021, filling a vacancy; term expires at 2024 annual meeting.","Standard non-employee director compensation, including option for 40,000 shares vesting monthly over 3 years.","Company will enter into a standard indemnification agreement with Dr. Ashworth.","No transactions exceeding $120,000 involving Dr. Ashworth; no arrangements for appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-290428","json":"https://secwatch.observer/filing/0001193125-21-290428.json","markdown":"https://secwatch.observer/filing/0001193125-21-290428.md","text":"https://secwatch.observer/filing/0001193125-21-290428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/0001193125-21-290428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/d233551d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T23:23:39.262364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b48eeb7e9d","claim":"Alan Ashworth was appointed as Class III director at CytomX Therapeutics, Inc..","evidence_excerpt":"On September 29, 2021, Alan Ashworth, Ph.D., FRS was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective September 29, 2021, as a Class III director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling a vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/0001193125-21-290428-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}